

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address; COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/029,506	12/21/2001	Hanuman B. Jampani	ETH-1601 (J&J 3.0-071)	4582
1815	7590 03/19/2003			
SELITTO, BEHR & KIM			EXAMINER	
203 MAIN STREET METUCHEN, NJ 08840-2727			FUBARA, BLESSING M	
,	, - , - , - , - , - , - , - , - , - , -		ART UNIT	PAPER NUMBER
			1615	
			DATE MAILED: 03/19/2003	3.

Please find below and/or attached an Office communication concerning this application or proceeding.

-		Application No.	Applicant(s)			
Office Action Summary		10/029,506	JAMPANI ET AL.			
		Examiner	Art Unit			
		Blessing M. Fubara	1615			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
Period for Reply						
THE N - Exter after - If the - If NO - Failui - Any r eame	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Is ions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period we to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing of patent term adjustment. See 37 CFR 1.704(b).	6(a). In no event, however, may a rep within the statutory minimum of thirty (ill apply and will expire SIX (6) MONTH cause the application to become ABAI	ly be timely filed 30) days will be considered timely. S from the mailing date of this communication. NDONED (35 U.S.C. § 133).			
Status	Responsive to communication(s) filed on					
1) <u>□</u> 2a) <u>□</u>						
3)□						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
·	on of Claims					
4) Claim(s) 1-45 is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.					
	5) Claim(s) is/are allowed.					
-	6) Claim(s) is/are rejected.					
	Claim(s) is/are objected to.	lection requirement				
8) Claim(s) <u>1-45</u> are subject to restriction and/or election requirement. Application Papers						
9) The specification is objected to by the Examiner.						
10) 🔲 -	The drawing(s) filed on is/are: a)□ accep	ted or b) objected to by the	e Examiner.			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)[The proposed drawing correction filed on	is: a) ☐ approved b) ☐ dis	approved by the Examiner.			
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
 a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. 						
Attachment(s)						
2) Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) D Notice of Inf	immary (PTO-413) Paper No(s) ormal Patent Application (PTO-152)			

DETAILED ACTION

Election Requirement

1. This application contains claims directed to the following patentably distinct species of the claimed invention: Many biocompatible compositions are claimed.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species (by electing specific cationic analgesic, specific antibiotic, specific antimicrobial, specific antiviral, specific anti-inflammatory, specific antidiabetic, specific anticholinergic, specific antidepressant, specific antihistamine, specific anticonvulsant, specific antimigrane, specific antineoplastic, specific antimalerials, specific immunosuppressants, specific cardiovascular drug or specific growth factor or hemostatic agents) for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, a biocompatible composition for delivery of pharmaceutically active agent is generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Application/Control Number: 10/029,506

Art Unit: 1615

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

If applicants desire additional components, examiner requests that applicants specifically name or completely name additional components. Claims containing additional components that are not specifically named or completely defined will be considered by the examiner as non-elected claims.

2. A telephone call was made to Ralph Selitto on 03/17/03 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

3. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Blessing M. Fubara whose telephone number is 703-308-8374. The examiner can normally be reached on 7 a.m. to 3:30 p.m. (Monday to Friday).

Application/Control Number: 10/029,506

Art Unit: 1615

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page can be reached on 703-308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3592 for regular communications and 703-305-3592 for After Final communications.

Page 4

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1234.

Blessing Fubara Algubara
Patent Framina Patent Examiner Tech. Center 1600

March 17, 2003